887254-66-2

Usage

Uses

Used in Organic Synthesis:
(R)-tert-butyl (1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)carbamate is used as a reagent in organic synthesis for its ability to facilitate the formation of more complex molecules. Its unique structure allows it to serve as a valuable intermediate in the synthesis process.
Used in Pharmaceutical Compound Preparation:
In the pharmaceutical industry, (R)-tert-butyl (1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)carbamate is used as a building block for the preparation of pharmaceutical compounds. Its incorporation into these compounds can potentially enhance their biological or industrial significance, making it a crucial component in drug development.
Used in Drug Development:
(R)-tert-butyl (1-(3-(4,4,5,5-ltetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)carbamate's potential applications extend to drug development, where its unique structure and properties can be harnessed to create new pharmaceuticals with improved efficacy and reduced side effects. Its role in this industry is to serve as a key intermediate in the synthesis of more complex molecules with potential therapeutic applications.
Used in the Production of Fine Chemicals:
(R)-tert-butyl (1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)carbamate also finds use in the production of fine chemicals, where its specific structural features can be exploited to create high-quality specialty chemicals for various applications, including but not limited to, the fragrance, flavor, and chemical industries.

Upstream product

• 1187932-25-7 (R)-tert-butyl (1-(3-bromophenyl)ethyl)carbamate 
• 73183-34-3 bis(pinacol)diborane 
• 887254-63-9 (R,S)-tert-butyl 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethylcarbamate 

Relevant academic research and scientific papers

Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway

Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system. Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria. Previously, we have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (1 and 2) binding to the open active conformation of FD. In continuation of our drug discovery program, we designed compounds applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases. We report herein the design, synthesis, and medicinal chemistry optimization of the benzylamine series culminating in the discovery of 12, an orally bioavailable and selective FD inhibitor. 12 demonstrated systemic suppression of AP activation in a lipopolysaccharide-induced AP activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.

AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF

The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical com

Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same

The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.